tannins and Crohn-Disease

The present prospective controlled study investigated the effect of a combination of 500 mg of tannin albuminate and 50 mg ethacridine lactate (Tannacomp) on chronic diarrhea in stable-phase Crohn's disease. Of the 30 patients admitted to the study, Crohn's disease was confined to the small intestine in 5, involved both small and large bowel in 11 patients, and only the large intestine in 14 cases.. Basic treatment was continued throughout the study; in addition, three times 2 tablets of Tannacomp were administered for 5 days, followed by a 5-day period of no such treatment, and then a further 5 days with the same regimen.. At the end of the treatment phases, there was a significant reduction in stool frequency from 5.5 +/- 0.6 (mean +/- SEM) to 4.0 +/- 0.8, and the summed score of the symptoms decreased from 6.3 +/- 0.6 to 5.3 +/- 0.6; in comparison with the initial situation or at the end of the five-day period of no additional treatment, the consistency of the stools also increased. The effect of Tannacomp showed a tendency to be more marked among patients with Crohn's disease limited to the large intestine, as compared with patients with small intestinal involvement. However, before Tannacomp can be recommended as treatment of chronic diarrhea in stable-phase Crohn's disease, further studies are needed.

Topics: Adult; Albumins; Antidiarrheals; Crohn Disease; Diarrhea; Drug Combinations; Drug Therapy, Combination; Ethacridine; Female; Humans; Hydrolyzable Tannins; Male; Pilot Projects; Tannins

Topics: Barium Sulfate; Colitis; Colitis, Ulcerative; Crohn Disease; Diagnosis, Differential; Feces; Humans; Radiography; Tannins

Topics: Aspartate Aminotransferases; Barium Sulfate; Chemical and Drug Induced Liver Injury; Coronary Disease; Crohn Disease; Diabetes Mellitus; Enema; Enteritis; Geriatrics; Hepatitis; Humans; Pharmacology; Research; Tannins; Transaminases